The goal of Dr. Luzum’s research is to use precision medicine, particularly genetics, to improve cardiovascular outcomes from medications. Adverse cardiac outcomes from drugs used to treat COVID-19 have recently been a major concern.
The COVID-19 pandemic continues to impact global health and safety. Numerous drugs are under expedited investigations, without well-established safety or efficacy data.
Patients who received single intravenous dose of tocilizumab were also more likely to leave the hospital or be off ventilator within a month, despite double the risk of additional infection
Recently published in the American Association on Intellectual and Developmental Disabilities (AAIDD), “Adverse Medication Events Related to Hospitalization in the United States: A Comparison Betwe
Sun Pharma Advanced Research Company (SPARC) and the University of Michigan are collaborating to kickstart research and development of potential new medications.
Prof. Steven Schwendeman and collaborators publish paper on a new long-acting, self-administered device that delivers hormones beneath the skin’s surface.